Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday 13, 2025. Robert A.

Amgen Inc. closed $84.79 short of its 52-week high ($346.85), which the company achieved on July 25th.

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...

Shares of Amgen Inc. AMGN slipped 1.01% to $258.59 Monday, on what proved to be an all-around mixed trading session for the ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $264.21 which represents a slight increase of $2.15 or 0.82% from the prior close of $262.06. The stock opened at $261.97 and touched a ...

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

Truist lowered the firm’s price target on Amgen (AMGN) to $298 from $333 and keeps a Hold rating on the shares as part of a broader research ...

Here's why Amgen increased its land holdings in New Albany, even though the pharma giant has plenty of room for expansion on ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Amgen (AMGN – Research Report), with a ...

Amgen's Imdylltra gets MHRA nod for ES-SCLC after two prior therapies, offering new hope for aggressive cancer with limited ...